Citigroup Cuts Teladoc Health (NYSE:TDOC) Price Target to $6.00

Teladoc Health (NYSE:TDOC) had its price target trimmed by Citigroup from $9.00 to $6.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a neutral rating on the health services provider’s stock.

Other equities research analysts also recently issued research reports about the company. Oppenheimer reduced their price target on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $9.00 target price (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Wells Fargo & Company decreased their price target on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 26th. Barclays started coverage on shares of Teladoc Health in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price objective for the company. Finally, TD Cowen reduced their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.56.

Teladoc Health Stock Performance

TDOC opened at $5.13 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67. The business has a fifty day simple moving average of $5.82 and a 200 day simple moving average of $7.14. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.90. The company has a market capitalization of $915.19 million, a PE ratio of -4.50 and a beta of 2.13.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $642.27 million for the quarter, compared to the consensus estimate of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. Teladoc Health’s revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Research analysts expect that Teladoc Health will post -1.16 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the transaction, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.58% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TDOC. Allianz Asset Management GmbH increased its holdings in Teladoc Health by 189.2% in the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after purchasing an additional 1,059,458 shares during the period. Vanguard Group Inc. grew its position in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after buying an additional 891,732 shares during the last quarter. Jupiter Asset Management Ltd. bought a new stake in shares of Teladoc Health in the 3rd quarter valued at about $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. increased its stake in shares of Teladoc Health by 23.1% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock valued at $1,841,000 after buying an additional 39,956 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Teladoc Health during the second quarter worth about $5,040,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.